secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2026-05-13T20:06:07+00:00
Accession:  0001104659-26-060232
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Journey Medical Q1 revenue $16M (+21% YoY); Emrosi sales triple to $6.3M
------------------------------------------------------------------------

- Total revenue $16.0M, +21% YoY vs $13.1M; Emrosi revenue $6.3M vs $2.1M in Q1 2025.
- Net loss narrowed to $2.2M ($0.08 loss per share) from $4.1M ($0.18 loss per share) YoY.
- Adjusted EBITDA turned positive at $0.6M ($0.02 per share) vs negative $0.9M in Q1 2025.
- Cash increased to $27M; gross margin 61% impacted by $1.3M non-cash API write-down.
- SG&A down $0.5M to $10.1M due to lower Emrosi launch costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/0001104659-26-060232-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-060232

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer